The mineralocorticoid Receptor Antagonist Tolerability Study (ARTS) (NCT01345656), a phase 2 trial, found that compared to a dose of 25–50 mg/day spironolactone, a dose of finerenone of 10 mg once daily or 5 mg twice daily leads to the same level of decrease in BNP and amino-terminal proBNP (indications of HF). Here, NR3C2 is linked to hydrops fetalis.